Sodium–Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Sodium–Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus

Published:2018-11 Issue:6 Volume:26 Page:312-320
ISSN:1061-5377
Container-title:Cardiology in Review
language:en
Short-container-title:

Author:

Dalan Rinkoo

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Reference86 articles.

1. Update of cardiovascular effects of older and newer anti-diabetic medications [published online ahead of print May 29, 2017].;Eleftheriadou;Curr Med Chem

2. Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice.;Avogaro;Cardiovasc Diabetol,2016

3. Liraglutide and cardiovascular outcomes in type 2 diabetes.;Marso;N Engl J Med,2016

4. Alogliptin after acute coronary syndrome in patients with type 2 diabetes.;White;N Engl J Med,2013

5. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes.;Green;N Engl J Med,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Dapagliflozin in Southern Europe Across the Spectrum of Characteristics of Type 2 Diabetes: An International Real-World Analysis;Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy;2022-11

2. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study;BMJ;2020-09-23

3. A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe;Diabetes Therapy;2019-12-20

4. Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis;Journal of Human Hypertension;2018-11-15

5. Sodium-glucose transporter 2 inhibition and cardiovascular events in patients with diabetes: information from clinical trials and observational real-world data;Clinical Science;2018-09-19